OP0126 A phase 2 study of safety and efficacy of anabasum (JBT-101) in systemic sclerosis
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.2712
Abstract: Background Anabasum (JBT-101) is a synthetic, oral, non-immunosuppressive, preferential CB2 agonist. It inhibits onset and activates resolution of innate immune responses in animal models of systemic sclerosis (SSc). Objectives Evaluate safety and efficacy of anabasum… read more here.
Keywords: anabasum subjects; none declared; safety; acr criss ... See more keywords